According to the data from 2025, some 16 percent of respondents said that rising health care costs were the most important health issue facing the United States. Cancer ranked second on the list with 15 percent. Issues with healthcare costsCurrently, the most urgent problem facing American healthcare is the high costs of care. The high expense of healthcare may deter people from getting the appropriate treatment when they need medical care or cause them to completely forego preventative care visits. Many Americans reported that they may skip prescription doses or refrain from taking medication as prescribed due to financial concerns. Such health-related behavior can result in major health problems, which may raise the long-term cost of care. Inflation, medical debt, and unforeseen medical expenses have all added to the burden that health costs are placing on household income. Gun violence issueThe gun violence epidemic has plagued the United States over the past few years, yet very little has been done to address the issue. In recent years, gun violence has become the leading cause of death among American children and teens. Even though more than half of Americans are in favor of tougher gun control regulations, there is little political will to strongly reform the current gun law. Gun violence has a deep traumatic impact on survivors and society, it is developing into a major public health crisis in the United States.

A 2024 survey found that over half of U.S. individuals indicated the cost of accessing treatment was the biggest problem facing the national healthcare system. This is much higher than the global average of 32 percent and is in line with the high cost of health care in the U.S. compared to other high-income countries. Bureaucracy along with a lack of staff were also considered to be pressing issues. This statistic reveals the share of individuals who said select problems were the biggest facing the health care system in the United States in 2024.

This survey displays the share of people in Virginia about what they think is the most important health issue faced in their state, as of April 2022. As much as 38 percent of the survey respondents believed that drug use, the opioid epidemic, or substance abuse are the most important health issue being faced by the people of Virginia.

According to the data from January 2024, 22 percent of respondents said that rising health care costs were the most important health issue facing the United States. Mental health ranked second on the list with 15 percent. Issues with healthcare costsCurrently, the most urgent problem facing American healthcare is the high costs of care. The high expense of healthcare may deter people from getting the appropriate treatment when they need medical care or cause them to completely forego preventative care visits. Many Americans reported that they may skip prescription doses or refrain from taking medication as prescribed due to financial concerns. Such health-related behavior can result in major health problems, which may raise the long-term cost of care. Inflation, medical debt, and unforeseen medical expenses have all added to the burden that health costs are placing on household income. Gun violence issueThe gun violence epidemic has plagued the United States over the past few years, yet very little has been done to address the issue. In recent years, gun violence has become the leading cause of death among American children and teens. Even though more than half of Americans are in favor of tougher gun control regulations, there is little political will to strongly reform the current gun law. Gun violence has a deep traumatic impact on survivors and society, it is developing into a major public health crisis in the United States.

We asked U.S. consumers about "Prevalence of health conditions" and found that "Mental health conditions (e.g., burnout, depression, anxiety)" takes the top spot, while "Deafness or hearing loss" is at the other end of the ranking.These results are based on a representative online survey conducted in 2025 among ****** consumers in the United States.

The New York Times is releasing a series of data files with cumulative counts of coronavirus cases in the United States, at the state and county level, over time. We are compiling this time series data from state and local governments and health departments in an attempt to provide a complete record of the ongoing outbreak.

Since late January, The Times has tracked cases of coronavirus in real time as they were identified after testing. Because of the widespread shortage of testing, however, the data is necessarily limited in the picture it presents of the outbreak.

We have used this data to power our maps and reporting tracking the outbreak, and it is now being made available to the public in response to requests from researchers, scientists and government officials who would like access to the data to better understand the outbreak.

The data begins with the first reported coronavirus case in Washington State on Jan. 21, 2020. We will publish regular updates to the data in this repository.

This data package contains dataset on prevalence rates of health conditions and diseases like obesity, diabetes and hearing loss and health risk factors for diseases like tobacco, alcohol and drug use.

Changelog:

Update September 20, 2021: Data and overview updated to reflect data used in the September 15 story Over Half of States Have Rolled Back Public Health Powers in Pandemic. It includes 303 state or local public health leaders who resigned, retired or were fired between April 1, 2020 and Sept. 12, 2021. Previous versions of this dataset reflected data used in the Dec. 2020 and April 2021 stories.

Overview

Across the U.S., state and local public health officials have found themselves at the center of a political storm as they combat the worst pandemic in a century. Amid a fractured federal response, the usually invisible army of workers charged with preventing the spread of infectious disease has become a public punching bag.

In the midst of the coronavirus pandemic, at least 303 state or local public health leaders in 41 states have resigned, retired or been fired since April 1, 2020, according to an ongoing investigation by The Associated Press and KHN.

According to experts, that is the largest exodus of public health leaders in American history.

Many left due to political blowback or pandemic pressure, as they became the target of groups that have coalesced around a common goal — fighting and even threatening officials over mask orders and well-established public health activities like quarantines and contact tracing. Some left to take higher profile positions, or due to health concerns. Others were fired for poor performance. Dozens retired. An untold number of lower level staffers have also left.

The result is a further erosion of the nation’s already fragile public health infrastructure, which KHN and the AP documented beginning in 2020 in the Underfunded and Under Threat project.

Findings

The AP and KHN found that:

• One in five Americans live in a community that has lost its local public health department leader during the pandemic
• Top public health officials in 28 states have left state-level departments ## Using this data To filter for data specific to your state, use this query

To get total numbers of exits by state, broken down by state and local departments, use this query

Methodology

KHN and AP counted how many state and local public health leaders have left their jobs between April 1, 2020 and Sept. 12, 2021.

The government tasks public health workers with improving the health of the general population, through their work to encourage healthy living and prevent infectious disease. To that end, public health officials do everything from inspecting water and food safety to testing the nation’s babies for metabolic diseases and contact tracing cases of syphilis.

Many parts of the country have a health officer and a health director/administrator by statute. The analysis counted both of those positions if they existed. For state-level departments, the count tracks people in the top and second-highest-ranking job.

The analysis includes exits of top department officials regardless of reason, because no matter the reason, each left a vacancy at the top of a health agency during the pandemic. Reasons for departures include political pressure, health concerns and poor performance. Others left to take higher profile positions or to retire. Some departments had multiple top officials exit over the course of the pandemic; each is included in the analysis.

Reporters compiled the exit list by reaching out to public health associations and experts in every state and interviewing hundreds of public health employees. They also received information from the National Association of City and County Health Officials, and combed news reports and records.

Public health departments can be found at multiple levels of government. Each state has a department that handles these tasks, but most states also have local departments that either operate under local or state control. The population served by each local health department is calculated using the U.S. Census Bureau 2019 Population Estimates based on each department’s jurisdiction.

KHN and the AP have worked since the spring on a series of stories documenting the funding, staffing and problems around public health. A previous data distribution detailed a decade's worth of cuts to state and local spending and staffing on public health. That data can be found here.

Attribution

Findings and the data should be cited as: "According to a KHN and Associated Press report."

Is Data Missing?

If you know of a public health official in your state or area who has left that position between April 1, 2020 and Sept. 12, 2021 and isn't currently in our dataset, please contact authors Anna Maria Barry-Jester annab@kff.org, Hannah Recht hrecht@kff.org, Michelle Smith mrsmith@ap.org and Lauren Weber laurenw@kff.org.

41,000 Americans lose their lives to suicide each yearIn 2016, suicide was the 9th leading cause of death among men and 16th leading cause of death among women in Pinal County.1 in 5 American adults have experienced a mental health issue.

A survey of adults in the United States found that around ** percent of respondents identified mobility issues, cancer, and cognitive decline as their top aging-related health concerns. This statistic depicts the percentage of adults in the United States who had select health concerns related to the aging process as of 2024.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases among people who received additional or booster doses were reported from 31 jurisdictions; 30 jurisdictions also reported data on deaths among people who received one or more additional or booster dose; 28 jurisdictions reported cases among people who received two or more additional or booster doses; and 26 jurisdictions reported deaths among people who received two or more additional or booster doses. This list will be updated as more jurisdictions participate. Incidence rate estimates: Weekly age-specific incidence rates by vaccination status were calculated as the number of cases or deaths divided by the number of people vaccinated with a primary series, overall or with/without a booster dose (cumulative) or unvaccinated (obtained by subtracting the cumulative number of people vaccinated with a primary series and partially vaccinated people from the 2019 U.S. intercensal population estimates) and multiplied by 100,000. Overall incidence rates were age-standardized using the 2000 U.S. Census standard population. To estimate population counts for ages 6 months through 1 year, half of the single-year population counts for ages 0 through 1 year were used. All rates are plotted by positive specimen collection date to reflect when incident infections occurred. For the primary series analysis, age-standardized rates include ages 12 years and older from April 4, 2021 through December 4, 2021, ages 5 years and older from December 5, 2021 through July 30, 2022 and ages 6 months and older from July 31, 2022 onwards. For the booster dose analysis, age-standardized rates include ages 18 years and older from September 19, 2021 through December 25, 2021, ages 12 years and older from December 26, 2021, and ages 5 years and older from June 5, 2022 onwards. Small numbers could contribute to less precision when calculating death rates among some groups. Continuity correction: A continuity correction has been applied to the denominators by capping the percent population coverage at 95%. To do this, we assumed that at least 5% of each age group would always be unvaccinated in each jurisdiction. Adding this correction ensures that there is always a reasonable denominator for the unvaccinated population that would prevent incidence and death rates from growing unrealistically large due to potential overestimates of vaccination coverage. Incidence rate ratios (IRRs): IRRs for the past one month were calculated by dividing the average weekly incidence rates among unvaccinated people by that among people vaccinated with a primary series either overall or with a booster dose. Publications: Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1284–1290. Johnson AG, Amin AB, Ali AR, et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021. MMWR Morb Mortal Wkly Rep 2022;71:132–138. Johnson AG, Linde L, Ali AR, et al. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination — 24 U.S. Jurisdictions, October 3, 2021–December 24, 2022. MMWR Morb Mortal Wkly Rep 2023;72:145–152. Johnson AG, Linde L, Payne AB, et al. Notes from the Field: Comparison of COVID-19 Mortality Rates Among Adults Aged ≥65 Years Who Were Unvaccinated and Those Who Received a Bivalent Booster Dose Within the Preceding 6 Months — 20 U.S. Jurisdictions, September 18, 2022–April 1, 2023. MMWR Morb Mortal Wkly Rep 2023;72:667–669.

Digital Health And Wellness Market Outlook

The global digital health and wellness market size was valued at approximately USD 150 billion in 2023 and is projected to reach nearly USD 600 billion by 2032, growing at a compound annual growth rate (CAGR) of 16.5% during the forecast period. This substantial growth is primarily driven by the increasing adoption of digital health technologies, the rising prevalence of chronic diseases, and the continuous advancements in healthcare IT infrastructure.

One of the major growth factors contributing to the expansion of the digital health and wellness market is the rising prevalence of chronic diseases such as diabetes, cardiovascular diseases, and respiratory disorders. With an aging global population and changing lifestyles, the burden of chronic diseases is escalating, necessitating efficient and innovative healthcare solutions. Digital health technologies, such as telehealth and remote monitoring, offer significant advantages in managing these conditions by facilitating timely interventions and continuous monitoring, thereby improving patient outcomes and reducing healthcare costs.

Another significant factor driving the market growth is the increasing penetration of smartphones and the internet, coupled with the growing awareness and acceptance of digital health solutions among consumers and healthcare providers. Mobile health (mHealth) applications are becoming essential tools for health management, providing users with easy access to health information, remote consultations, and personalized health tracking. The convenience and accessibility offered by these digital health tools are encouraging more individuals to adopt them, leading to a surge in demand and market expansion.

The continuous advancements in healthcare IT infrastructure and the integration of advanced technologies such as artificial intelligence (AI), big data analytics, and the Internet of Things (IoT) are further propelling the digital health and wellness market. These technologies enable more precise diagnostics, personalized treatment plans, and efficient healthcare delivery. For instance, AI-powered algorithms can analyze vast amounts of health data to identify patterns and predict potential health issues, while IoT devices facilitate seamless data exchange between patients and healthcare providers, enhancing the overall efficiency of healthcare services.

Regionally, North America is leading the digital health and wellness market, driven by the high adoption rate of advanced healthcare technologies, supportive government policies, and significant investments in healthcare IT infrastructure. The United States, in particular, is at the forefront, with numerous digital health startups and established firms actively innovating in this space. However, other regions such as Europe and Asia Pacific are also witnessing substantial growth, fueled by increasing healthcare expenditures, rising awareness about digital health solutions, and the expansion of telehealth services.

Connected Health Solutions are becoming increasingly pivotal in the digital health and wellness market, as they offer a seamless integration of various healthcare services through digital platforms. These solutions enable real-time communication and data sharing between patients and healthcare providers, enhancing the quality and efficiency of care. By leveraging technologies such as IoT and AI, Connected Health Solutions facilitate continuous monitoring and personalized healthcare, which is particularly beneficial for managing chronic conditions. The ability to connect different healthcare systems and devices ensures that patients receive comprehensive and coordinated care, reducing the risk of errors and improving overall health outcomes. As the demand for integrated healthcare solutions grows, Connected Health Solutions are set to play a crucial role in transforming the healthcare landscape.

Component Analysis

The digital health and wellness market is segmented by component into software, hardware, and services. Each component plays a crucial role in the functionality and efficiency of digital health solutions, and their interplay determines the overall effectiveness of digital health systems. Software, as a component, encompasses a wide array of applications, including electronic health records (EHRs), telehealth platforms, a

As of August 2024, some 20 percent of Americans surveyed were of the opinion that opioids and fentanyl addiction is the number one public health threat in the U.S., a significant decrease from 24 percent in June 2024. Furthermore, obesity was viewed as a top public health issue by 19 percent of Americans in August 2024.
U.S. healthcare issues The United States has the highest healthcare spending globally. The majority of Americans considered rising healthcare costs as the most important healthcare problem facing the U.S. in January 2023. While COVID-19 and cancer were ranked second on the list. Due to unfortunate mass shooting incidents in the country, gun violence is typically related to homicide and is not considered a healthcare issue. Although the most popular method of suicide among Americans who attempted it was a gun or firearm, the link between gun access and suicide is frequently ignored as a public health crisis.

This dataset contains model-based census tract estimates. PLACES covers the entire United States—50 states and the District of Columbia—at county, place, census tract, and ZIP Code Tabulation Area levels. It provides information uniformly on this large scale for local areas at four geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. The dataset includes estimates for 40 measures: 12 for health outcomes, 7 for preventive services use, 4 for chronic disease-related health risk behaviors, 7 for disabilities, 3 for health status, and 7 for health-related social needs. These estimates can be used to identify emerging health problems and to help develop and carry out effective, targeted public health prevention activities. Because the small area model cannot detect effects due to local interventions, users are cautioned against using these estimates for program or policy evaluations. Data sources used to generate these model-based estimates are Behavioral Risk Factor Surveillance System (BRFSS) 2022 or 2021 data, Census Bureau 2020 population data, and American Community Survey 2018–2022 estimates. The 2024 release uses 2022 BRFSS data for 36 measures and 2021 BRFSS data for 4 measures (high blood pressure, high cholesterol, cholesterol screening, and taking medicine for high blood pressure control among those with high blood pressure) that the survey collects data on every other year. More information about the methodology can be found at www.cdc.gov/places.

Snapshot img

US Behavioral Health Market Size 2025-2029

The US behavioral health market size is forecast to increase by USD 9.17 billion at a CAGR of 4.2% between 2024 and 2029.

The market is experiencing significant growth, driven by the increasing prevalence of behavioral disorders and the advent of digital health solutions. Telehealth and telemedicine, including video conferencing, have become catalysts for delivering mental health services, particularly in areas with a shortage of skilled professionals. The use of digital software and tools is transforming the way mental health services are delivered, making them more accessible and convenient for patients. Furthermore, the legalization of marijuana for medicinal purposes in some US states is also impacting the market, as it provides an alternative treatment option for certain behavioral disorders.


These trends are expected to continue, as insurers increasingly cover telehealth services and technology continues to advance. However, challenges such as data security and privacy concerns, as well as the need for standardized telehealth regulations, must be addressed to ensure the effective and safe delivery of behavioral health services.

What will be the Size of the market During the Forecast Period?

Request Free Sample

The market encompasses a range of mental and emotional disorders, including forensic psychiatry, drug abuse, family therapy, perinatal mental health, interpersonal therapy, peer support, eating disorders, post-traumatic stress disorder, biopsychosocial assessment, stress management, public health, geriatric psychiatry, mindfulness-based stress reduction, autism spectrum disorder, attention-deficit/hyperactivity disorder, crisis hotlines, group therapy, healthcare access, holistic health, suicide prevention, support groups, psychotropic medications, opioid use disorder, community resources, developmental disabilities, health disparities, harm reduction, health equity, motivational interviewing, mood stabilizers, alcohol use disorder, and obsessive-compulsive disorder. 


This vast market is driven by increasing awareness and acceptance of mental health issues, growing prevalence of mental disorders, and advancements in treatment methods. The market is expected to grow significantly due to the rising burden of mental health conditions, increasing healthcare spending, and the availability of new technologies and therapies. The market is also influenced by public health initiatives, policy changes, and societal trends towards holistic health and wellness.

How is this market segmented, and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

End-user

  Inpatient hospital treatment services
  Outpatient counselling
  Home-based treatment services
  Emergency mental health services


Type

  Substance abuse disorders
  Alcohol use disorders
  Eating disorders
  ADHD
  Others


Age Group

  Adult
  Geriatric
  Pediatric


Geography

  US

By End-user Insights

The inpatient hospital treatment services segment is estimated to witness significant growth during the forecast period. Behavioral health services encompass a range of treatments for mental health conditions and substance use disorders. Inpatient hospital treatment, which includes medication management and regular check-ups, involves shorter stays compared to residential or home-based services. The high cost of inpatient hospital treatment is a significant factor, making it an essential component of the market. The prevalence of behavioral health conditions, such as anxiety, depression, substance use disorder, attention-deficit/hyperactivity disorder (ADHD), bipolar disorder, and more, is substantial in the US. The high number of hospital admissions due to substance abuse is expected to drive the growth of the inpatient hospital treatment segment during the forecast period.
Care coordination, a critical aspect of behavioral health services, is facilitated through electronic health records and health information technology. Crisis intervention, trauma-sensitive care, and trauma-informed care are essential components of mental wellness and recovery support. Value-based care models, such as partial hospitalization and intensive outpatient programs, are increasingly being adopted to improve quality and reduce healthcare costs. Mental health policy, clinical trials, and behavioral health research are essential for advancing evidence-based practices, such as dialectical behavior therapy and cognitive behavioral therapy. Virtual care, employee assistance programs, patient education, and school-based services are also crucial components of the market. Machine learning, data analytics, and artificial intel

Treatment for Mental Health Market Outlook

As of 2023, the global market size for mental health treatment was valued at approximately $250 billion and is anticipated to reach $400 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 5.5%. The increasing recognition of mental health issues as critical components of overall health, along with technological advancements in treatment methodologies, is propelling the growth of this market.

A significant growth factor for the mental health treatment market is the rising prevalence of mental health disorders worldwide. The World Health Organization (WHO) reports that depression affects more than 264 million people globally, making it one of the leading causes of disability. The increasing awareness campaigns and educational programs aimed at reducing stigma and encouraging individuals to seek help are also contributing significantly to market growth. Furthermore, governments and private organizations are increasingly investing in mental health infrastructure, policies, and research, thereby boosting the market.

Technological advancements in mental health treatment are another crucial growth driver. The adoption of telemedicine and telepsychiatry has surged, especially in the wake of the COVID-19 pandemic. These technologies offer easier access to mental health services, which is particularly beneficial for individuals in remote areas. Additionally, the development of mobile apps and platforms for cognitive behavioral therapy (CBT) and other therapeutic techniques is making mental health care more accessible and efficient. Innovations in pharmacotherapy, including personalized medicine and the development of new drugs with fewer side effects, are also contributing to market expansion.

Another driving factor is the growing societal acceptance and reduced stigma surrounding mental health issues. Historically, mental health was a taboo topic in many cultures, leading to reluctance in seeking treatment. However, public figures and widespread media campaigns advocating for mental health awareness have significantly shifted public perception. This change is resulting in higher diagnosis rates and more individuals seeking professional help, thereby bolstering market growth. The role of community and peer support groups should not be underestimated, as these social structures encourage individuals to seek and maintain treatment.

When considering the regional outlook, North America holds the largest share of the mental health treatment market due to its advanced healthcare infrastructure and significant investments in mental health. The region also benefits from high levels of awareness and a strong presence of leading market players. Europe follows closely, driven by concerted efforts to integrate mental health services into primary care systems. The Asia Pacific region is expected to witness the highest CAGR, attributed to rapidly developing healthcare infrastructure, increasing awareness, and rising disposable incomes. Latin America and the Middle East & Africa are also seeing growth, though at a slower rate, due to improving healthcare policies and increasing international collaborations.

Psychotherapy Analysis

Psychotherapy remains one of the most commonly employed treatment modalities for mental health disorders. It encompasses various approaches, such as cognitive-behavioral therapy (CBT), dialectical behavior therapy (DBT), psychodynamic therapy, and more. The versatility of psychotherapy in addressing a wide range of mental health issues—from depression and anxiety to more severe conditions like schizophrenia—makes it a cornerstone of mental health treatment. The increasing endorsement of psychotherapy by medical professionals and its proven efficacy in numerous studies are major factors driving its adoption. Additionally, insurance companies are increasingly covering psychotherapy sessions, making them more accessible to a broader population.

The rise of online therapy platforms has revolutionized the psychotherapy segment. Companies like BetterHelp and Talkspace offer virtual therapy sessions, breaking geographical barriers and making mental health treatment accessible from the comfort of one’s home. This trend has gained additional traction during the COVID-19 pandemic, as lockdowns and social distancing measures necessitated remote solutions. Online therapy platforms also offer anonymity, which can be particularly appealing to individuals reluctant to seek in-person therapy due to stigma or privacy concerns.

Cognitive-behavioral therapy (CBT) is partic

This catalog record includes detailed variable-level descriptions, enabling data discovery and comparison. The data are not archived at ICPSR. Users should consult the data owners (via the Roper Center for Public Opinion Research) directly for details on obtaining the data. This collection includes variable-level metadata of Latinos' Lives and Health Today, a survey from National Public Radio, the Harvard School of Public Health, and the Robert Wood Johnson Foundation, conducted by Social Science Research Solutions (SSRS). Topics covered in this survey include: Satisfaction with life Satisfaction with living area Most important local issue Other Hispanic people in living area Rating aspects of life Personal discrimination in past twelve months Personal finances Achieving American dream Economic class Better off than parents Opportunities for children Language spoken at home Looking for job Concerns about unemployment Biggest health problem in family Description of weight Trying to lose weight Medical care in past twelve months Problems with medical care access Confidence in ability to pay for major illness Health care facility used Health care professionals speaking Spanish Receiving poor medical care Health insurance coverage Personal health rating Frequency of exercise Country born in Age came to United States Parents' birth country Reasons for coming to US Comparing birth country to US Diet as more or less healthy in US. The data and documentation files for this survey are available through the Roper Center for Public Opinion Research [Roper #31092358]. Frequencies and summary statistics for the 184 variables from this survey are available through the ICPSR social science variable database and can be accessed from the Variables tab.

Digital Health Market Outlook

According to our latest research, the global digital health market size reached USD 287.7 billion in 2024, reflecting a robust expansion driven by technological advancements and healthcare digitization. The market is experiencing a healthy compound annual growth rate (CAGR) of 16.2% from 2025 to 2033. By the end of 2033, the global digital health market is forecasted to reach USD 888.4 billion. This significant growth is primarily propelled by the increasing adoption of digital health solutions, the proliferation of mobile health technologies, and the rising demand for remote healthcare services. As per our comprehensive analysis, the digital health market continues to evolve rapidly, underpinned by ongoing innovations in telehealth, mobile health (mHealth), digital therapeutics, and wearable technologies.

The growth trajectory of the digital health market is strongly influenced by the escalating prevalence of chronic diseases and the need for cost-effective healthcare delivery. With the global population aging and lifestyle-related health issues on the rise, healthcare providers are increasingly leveraging digital platforms to manage patient care more efficiently. Remote monitoring technologies, telehealth consultations, and mobile health applications are enabling continuous patient engagement and early intervention, which not only improves clinical outcomes but also reduces the burden on traditional healthcare infrastructures. The COVID-19 pandemic has further accelerated this shift, as restrictions on in-person visits highlighted the necessity for robust digital health ecosystems. This transformation is expected to persist, with digital health becoming an integral part of mainstream healthcare delivery models.

Another key growth factor is the rapid advancement in digital health technologies, particularly in areas such as artificial intelligence (AI), big data analytics, and cloud computing. These innovations are enhancing the functionality and scalability of digital health platforms, enabling personalized medicine, predictive analytics, and real-time decision support for clinicians. The integration of AI-powered diagnostic tools and health analytics solutions is streamlining clinical workflows, optimizing resource allocation, and facilitating data-driven healthcare management. Moreover, the widespread adoption of smartphones and wearable devices has democratized access to health information, empowering individuals to proactively monitor their health and wellness. This shift towards patient-centric care is fostering a culture of preventive healthcare, which is expected to drive sustained demand for digital health solutions over the forecast period.

Regulatory support and strategic investments are also playing a pivotal role in shaping the digital health market landscape. Governments across the globe are implementing favorable policies, funding initiatives, and reimbursement frameworks to promote the adoption of digital health solutions. For instance, the expansion of telehealth reimbursement policies in major markets such as the United States and Europe has incentivized healthcare providers to integrate digital platforms into their service offerings. Additionally, venture capital investments in digital health startups are fueling innovation and market entry, leading to a vibrant ecosystem of technology providers, healthcare organizations, and payers. These collaborative efforts are fostering interoperability, data security, and standardization, which are critical for the seamless integration of digital health into existing healthcare systems.

From a regional perspective, North America currently dominates the digital health market, accounting for the largest share in 2024, followed by Europe and Asia Pacific. The high adoption rate of digital health technologies in North America can be attributed to advanced healthcare infrastructure, supportive regulatory policies, and a tech-savvy population. Europe is witnessing significant growth, driven by increasing investments in digital health innovation and cross-border healthcare initiatives. Meanwhile, Asia Pacific is emerging as a high-growth region, fueled by rising healthcare expenditures, government-led digitalization programs, and the growing penetration of mobile technologies. Latin America and the Middle East & Africa are also showing promising potential, albeit at a comparatively nascent stage, as stakeholders focus on expanding healthcare access and improving quality of care through d

The global women's health market is predicted to reach a value of XXX million by 2033, with a CAGR of XX% during the forecast period (2025-2033). The market is driven by factors such as the rising prevalence of chronic diseases among women, increased awareness of women's health issues, and the growing demand for personalized and tailored healthcare solutions. Key trends in the market include the increasing adoption of telemedicine and digital health technologies, the growing focus on preventive care, and the development of innovative therapies and treatments for women's health conditions. The market is segmented based on application, type, and region. The major applications of women's health products and services include contraception, fertility treatments, prenatal care, gynecological care, and menopause management. The different types of products and services available in the market include pharmaceuticals, devices, diagnostics, and treatments. Regionally, the market is segmented into North America, South America, Europe, the Middle East & Africa, and Asia Pacific. North America is the largest market for women's health products and services, followed by Europe and Asia Pacific. The Middle East & Africa and South America are expected to witness significant growth in the coming years due to the increasing prevalence of chronic diseases among women and the rising demand for healthcare services.

Note: Reporting of new COVID-19 Case Surveillance data will be discontinued July 1, 2024, to align with the process of removing SARS-CoV-2 infections (COVID-19 cases) from the list of nationally notifiable diseases. Although these data will continue to be publicly available, the dataset will no longer be updated.

Authorizations to collect certain public health data expired at the end of the U.S. public health emergency declaration on May 11, 2023. The following jurisdictions discontinued COVID-19 case notifications to CDC: Iowa (11/8/21), Kansas (5/12/23), Kentucky (1/1/24), Louisiana (10/31/23), New Hampshire (5/23/23), and Oklahoma (5/2/23). Please note that these jurisdictions will not routinely send new case data after the dates indicated. As of 7/13/23, case notifications from Oregon will only include pediatric cases resulting in death.

This case surveillance public use dataset has 12 elements for all COVID-19 cases shared with CDC and includes demographics, any exposure history, disease severity indicators and outcomes, presence of any underlying medical conditions and risk behaviors, and no geographic data.

CDC has three COVID-19 case surveillance datasets:

• COVID-19 Case Surveillance Public Use Data with Geography: Public use, patient-level dataset with clinical data (including symptoms), demographics, and county and state of residence. (19 data elements)
• COVID-19 Case Surveillance Public Use Data: Public use, patient-level dataset with clinical and symptom data and demographics, with no geographic data. (12 data elements)
• COVID-19 Case Surveillance Restricted Access Detailed Data: Restricted access, patient-level dataset with clinical and symptom data, demographics, and state and county of residence. Access requires a registration process and a data use agreement. (33 data elements)

• Data elements can be found on the COVID-19 case report form located at www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf.
• Data are considered provisional by CDC and are subject to change until the data are reconciled and verified with the state and territorial data providers.
• Some data cells are suppressed to protect individual privacy.
• The datasets will include all cases with the earliest date available in each record (date received by CDC or date related to illness/specimen collection) at least 14 days prior to the creation of the current datasets. This 14-day lag allows case reporting to be stabilized and ensures that time-dependent outcome data are accurately captured.
• Datasets are updated monthly.
• Datasets are created using CDC’s Policy on Public Health Research and Nonresearch Data Management and Access and include protections designed to protect individual privacy.
• For more information about data collection and reporting, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/about-us-cases-deaths.html.
• For more information about the COVID-19 case surveillance data, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/faq-surveillance.html
  

Overview

The COVID-19 case surveillance database includes individual-level data reported to U.S. states and autonomous reporting entities, including New York City and the District of Columbia (D.C.), as well as U.S. territories and affiliates. On April 5, 2020, COVID-19 was added to the Nationally Notifiable Condition List and classified as “immediately notifiable, urgent (within 24 hours)” by a Council of State and Territorial Epidemiologists (CSTE) Interim Position Statement (Interim-20-ID-01). CSTE updated the position statement on August 5, 2020, to clarify the interpretation of antigen detection tests and serologic test results within the case classification (Interim-20-ID-02). The statement also recommended that all states and territories enact laws to make COVID-19 reportable in their jurisdiction, and that jurisdictions conducting surveillance should submit case notifications to CDC. COVID-19 case surveillance data are collected by jurisdictions and reported voluntarily to CDC.

For more information: NNDSS Supports the COVID-19 Response | CDC.

The deidentified data in the “COVID-19 Case Surveillance Public Use Data” include demographic characteristics, any exposure history, disease severity indicators and outcomes, clinical data, laboratory diagnostic test results, and presence of any underlying medical conditions and risk behaviors. All data elements can be found on the COVID-19 case report form located at www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf.

COVID-19 Case Reports

COVID-19 case reports have been routinely submitted using nationally standardized case reporting forms. On April 5, 2020, CSTE released an Interim Position Statement with national surveillance case definitions for COVID-19 included. Current versions of these case definitions are available here: https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2021/.

All cases reported on or after were requested to be shared by public health departments to CDC using the standardized case definitions for laboratory-confirmed or probable cases. On May 5, 2020, the standardized case reporting form was revised. Case reporting using this new form is ongoing among U.S. states and territories.

Data are Considered Provisional

• The COVID-19 case surveillance data are dynamic; case reports can be modified at any time by the jurisdictions sharing COVID-19 data with CDC. CDC may update prior cases shared with CDC based on any updated information from jurisdictions. For instance, as new information is gathered about previously reported cases, health departments provide updated data to CDC. As more information and data become available, analyses might find changes in surveillance data and trends during a previously reported time window. Data may also be shared late with CDC due to the volume of COVID-19 cases.
• Annual finalized data: To create the final NNDSS data used in the annual tables, CDC works carefully with the reporting jurisdictions to reconcile the data received during the year until each state or territorial epidemiologist confirms that the data from their area are correct.
• Access Addressing Gaps in Public Health Reporting of Race and Ethnicity for COVID-19, a report from the Council of State and Territorial Epidemiologists, to better understand the challenges in completing race and ethnicity data for COVID-19 and recommendations for improvement.

Data Limitations

To learn more about the limitations in using case surveillance data, visit FAQ: COVID-19 Data and Surveillance.

Data Quality Assurance Procedures

CDC’s Case Surveillance Section routinely performs data quality assurance procedures (i.e., ongoing corrections and logic checks to address data errors). To date, the following data cleaning steps have been implemented:

• Questions that have been left unanswered (blank) on the case report form are reclassified to a Missing value, if applicable to the question. For example, in the question “Was the individual hospitalized?” where the possible answer choices include “Yes,” “No,” or “Unknown,” the blank value is recoded to Missing because the case report form did not include a response to the question.
• Logic checks are performed for date data. If an illogical date has been provided, CDC reviews the data with the reporting jurisdiction. For example, if a symptom onset date in the future is reported to CDC, this value is set to null until the reporting jurisdiction updates the date appropriately.
• Additional data quality processing to recode free text data is ongoing. Data on symptoms, race and ethnicity, and healthcare worker status have been prioritized.

Data Suppression

To prevent release of data that could be used to identify people, data cells are suppressed for low frequency (<5) records and indirect identifiers (e.g., date of first positive specimen). Suppression includes rare combinations of demographic characteristics (sex, age group, race/ethnicity). Suppressed values are re-coded to the NA answer option; records with data suppression are never removed.

For questions, please contact Ask SRRG (eocevent394@cdc.gov).

Additional COVID-19 Data

COVID-19 data are available to the public as summary or aggregate count files, including total counts of cases and deaths by state and by county. These